Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
about
Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targetsPCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancerActive surveillance and focal therapy for low-intermediate risk prostate cancerERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal originAssociation of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.A kernel-based integration of genome-wide data for clinical decision support.Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.Neighborhood rough set reduction-based gene selection and prioritization for gene expression profile analysis and molecular cancer classification.Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot studyFinding minimum gene subsets with heuristic breadth-first search algorithm for robust tumor classification.Oncogenic gene fusions in epithelial carcinomasEvidence for field cancerization of the prostate.Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostatesMarkers of field cancerization: proposed clinical applications in prostate biopsiesHeterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisMarkers for detection of prostate cancer.Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer ProgressionDisruption of prostate epithelial differentiation pathways and prostate cancer development.Anterior tumors of the prostate: clinicopathological features and outcomes.Management of low risk prostate cancer-active surveillance and focal therapy.Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells.Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers.Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.ERG oncogene modulates prostaglandin signaling in prostate cancer cells.Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationGene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.ETS gene fusions and prostate cancer.Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusionClonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
P2860
Q24629083-F8668316-0A49-4743-915C-9E36BBCFE8E8Q26752933-4287787E-D769-48E7-AF0A-CA48925FA563Q26773641-DCEF219E-E2C3-4F59-890A-9958C03EE94EQ31005436-BF599A5B-DFFA-4BAE-AB8E-8D84854311E0Q33359279-5C75B3BC-1555-4C68-AC10-2541000E521CQ33428301-E8D8BBEF-2B5F-44FA-8300-52EA2D273CF0Q33714055-14B6C1DE-3D0F-403C-9F09-7262DF9B4544Q33960955-E7834DF3-AA17-4473-89A6-BE650D4296ECQ34084882-083EC261-762A-4C71-B68F-47A9F7B0CDA7Q34351520-C308ECD4-A664-470E-B5CD-18F045603E65Q34949690-1688BB9A-92C1-4744-B5BD-289CCD35338DQ34982560-7A666E05-91FE-4A5D-BA7B-C0A74DF499FEQ35685920-2FDF1B9A-3DBB-4D39-BDDB-8E51C09F0B1CQ35751842-7EB25CE4-76A3-4ED2-8555-5D1548DEAAE2Q35991148-7DEE84CA-7AA8-403F-B51C-8DECBDBBD1FFQ36105102-F1A875C4-DCC9-463A-A879-DADAD33EB4EDQ36469889-BE7BD73C-7A95-4881-B159-97FD4463A192Q36800086-2BD47FF8-8730-4549-AE28-C757DD982957Q36848024-950B101D-E834-4C53-8611-21DA3F02EBBBQ36899790-C39A2603-8EE6-48FA-B78D-66FCF8BC3497Q37328403-65F41574-B3B7-4FC4-9DEC-22307ADE48EDQ37527876-2E4528CB-DB25-4C40-98B5-01D0337AEC15Q38069582-AF535880-4845-4911-99A7-9A5D43641E58Q38160495-92A9CB7A-5F43-4D6C-8899-9E139549C307Q38168064-DB35B3DF-20D8-4C84-BCC2-DD917070E9ABQ38211360-70830BCA-69D3-470D-9066-D67244721F97Q38300608-5EA71EBC-5A06-4C7B-B918-96A2DC756EA3Q38301071-8CDDD1CC-E2B7-4EC5-BEAA-AE6FF845D64CQ38723072-B3485FF6-B513-4DB6-9E07-520BEFB842A4Q39616982-D0D45242-1C8A-46E5-A0F5-2E4C20DDA405Q39643971-B14239C2-ED9E-479A-8463-44E80E612CBBQ41132392-2283AF28-0452-4763-86F4-2DFA84A17E05Q41192868-2A9BD450-DD7B-466F-989B-D84B484A913DQ41489983-F8E462FC-B548-47B4-AC81-7074B48244C4Q41609967-8A5C19CB-2573-434E-A05B-EC84E99A01CFQ41854285-EF60DE44-E545-4A56-8B1B-A718987A43D6Q42064904-3B004F5F-AB18-40BA-9D0D-A1B48D12B135Q42068278-DB85C7DC-E854-452F-84E2-574CCAF012ABQ42119481-CE13FE51-BD28-4444-96D1-3D3CBB0344F0Q42120206-31BCFB53-2416-462D-984C-C17BB0B19610
P2860
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
@en
type
label
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
@en
prefLabel
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
@en
P2093
P1433
P1476
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
@en
P2093
Albert Dobi
Chun-Ling Gao
David G McLeod
Gyorgy Petrovics
Isabell A Sesterhenn
Jennifer Cullen
Lakshmi Ravindranath
Shiv Srivastava
Yongmei Chen
P2888
P356
10.1038/MODPATHOL.3800981
P577
2007-12-07T00:00:00Z
P5875
P6179
1019875157